|
TITLE OF THE INVENTION
The present invention relates to new heterocyclic aminomethyl compounds.
DESCRIPTION OF THE PRIOR ART
Numerous heterocyclic alkylamines containing a benzoxazolinone, benzothiazolinone or benzoxazinone moiety have already been described.
European Patent EP 0 110781 describes 6-(2-aminoethyl)benzoxazolinones as hypnotics and agents for the treatment of cardiac insufficiency. European Patent Application EP 0 281 309 describes compounds of piperazinoethyl- or -butylbenzoxazolinone and -benzothiazolinone structure which are useful as antipsychotics.
French Patent FR 2035749 describes aminoalkylbenzoxazinones which are useful for the treatment of central nervous system disorders.
The publication "II farmaco" 89, 44 (1), 77-88 describes arylpiperazinobutylbenzoxazolinones as well as their essentially analgesic properties.
Patent Application EP 0 223674 describes 7-acylbenzoxazinones and their derivatives as possessing antiatherosclerotic and normolipemic properties.
Patent Application EP 0 478446 describes heterocyclic ethyl- and butylamines which possess the property of binding with very high affinity to the 5-HT.sub.1A serotoninergic receptors.
BACKGROUND OF THE INVENTION
The Applicant has now discovered new heterocyclic aminomethyl compounds, more especially aminomethylbenzoxazolinone, -benzothiazolinone and -benzoxazinone compounds, which, contrary to the compounds of the prior art and most surprisingly, no longer have other than a weak affinity for the 5-HT.sub.1A and D.sub.2 receptors. At the same time, these new compounds possess excellent affinity for the D.sub.4 receptors, whereas a comparison carried out on the compounds mentioned in the documents of the prior art established, in effect, that the latter compounds had no affinity for these D.sub.4 receptors.
The D.sub.4 receptors are localized in the corticolimbic structures (frontal cortex, nucleus accumbens and hippocampus) involved in the control of mood and memory (Bloom and Kupfer, in Psychopharmacology "The fourth generation of progress" Raven Press, New York 1995; Meador-Woodruff et al., "Dopamine receptor mRNA expression in human striatum and neocortex". Neuropsychopharmacology, 1996; 15:17-29). In these structures, a subpopulation is localized on the GABAergic type neurons, which also play a key part in the modulation of mood and of the cognitive functions (Bloom and Kupfer, 1995 (already cited)); Mrzkjak et al., "Localisation of dopamine D.sub.4 receptors in GABAergic neurons of the primate brain". Nature, 1996; 381:245-248). Some studies have shown an increase in the density of the D.sub.4 receptors in psychotic patients, while clozapine shows a high affinity for the D.sub.4 receptors (Van Tol et al., "Cloning of the gene for a human dopamine D.sub.4 receptor with high affinity for the antipsychotic clozapine". Nature, 1991; 350:610-614). In addition, noradrenaline, a neurotransmitter involved in psychotic, anxiety and depressive states as well as cognitive and attention disorders (Bloom and Kupfer, 1995 (already cited)), possesses a high affinity for the D.sub.4 receptors (Lanau et al., "Epinephrine and norepinephrine act as potent agonists at the human recombinant D.sub.4.4 receptor". Am. Soc. Neurosci., 1995; 21:252.2). These results demonstrate the value of the products of the invention in the treatment of schizophrenia, anxiety, depression, drug abuse, impulsive states (e.g. aggressiveness) and mnemocognitive disorders. Furthermore, the high concentration of D.sub.4 receptors in the superficial layer of the spinal cord (Matsumoto et al., "Low levels of mRNA for dopamine D.sub.4 receptor in human cerebral cortex and striatum". J. Neurochem., 1996; 66: 915-919) suggests a value in the treatment of painful (e.g. neuropathic or migrainous) states.
DETAILED DESCRIPTION OF THE INVENTION
More specifically, the present invention relates to the compounds of general formula (I): ##STR2## in which: R.sub.1 represents a hydrogen atom or a lower alkyl group, or alternatively
R.sub.1 represents a group ##STR3## in which m represents an integer between 1 and 4 inclusive and Ar.sub.1 represents
either a group CO--Ar.sub.2 where Ar.sub.2 represents a phenyl ring unsubstituted or substituted with one or more radicals chosen from halogen, hydroxyl, lower alkyl, trifluoromethyl or lower alkoxy,
or a group .dbd.C--(Ar.sub.2).sub.2 where Ar.sub.2 has the same meaning as above,
n represents 0 or 1
A represents an oxygen or sulfur atom
X represents a CH.sub.2 group or a single bond
Y represents a CH group or a nitrogen atom
Ar represents a phenyl or naphthyl group optionally substituted with one, two or three groups chosen from halogen, hydroxyl, lower alkoxy, lower alkyl, (lower alkoxy)(lower alkyl), trifluoromethyl or aminosulfonyl, or Ar represents a pyridyl or pyrimidinyl group or a 3-(benzod!1,2-thiazolyl) group also known as a 3-benzisothiazolyl group: ##STR4## where appropriate their isomers, pure or mixed, as well as their addition salts with a pharmaceutically acceptable acid, or a pharmaceutically acceptable base when R.sub.1 .dbd.H on the understanding that, except where otherwise stated,
the terms "lower alkyl" and "lower alkoxy" correspond to linear or branched groups containing from 1 to 6 carbon atoms.
Among pharmaceutically acceptable acids, there may be mentioned, without implied limitation, hydrochloric, sulfuric, tartaric, maleic, fumaric, oxalic, methanesulfonic, camphoric, ethanesulfonic, citric, and the like, acids.
Among pharmaceutically acceptable bases, there may be mentioned, without implied limitation, sodium, potassium and calcium hydroxides as well as sodium, potassium, calcium, and the like, carbonates.
The invention relates preferentially to the compounds of formula (I) for which, taken together or separately:
R.sub.1 is a hydrogen atom, a methyl group or a group ##STR5## for which m equals 2 and Ar.sub.1 represents either a ##STR6## group or alternatively a ##STR7## group
A is a sulfur atom and X represents a single bond; the compounds are then derivatives of benzoxazolinone of formula: ##STR8##
A is an oxygen atom and X represents a single bond; the compounds are then derivatives of benzothiazolinone of formula ##STR9##
A is an oxygen atom and X represents a CH.sub.2 group; these compounds are derivatives of benzoxazinone of formula ##STR10## the side chain is grafted at position c n represents 0
Y represents a nitrogen atom
Ar represents a phenyl group substituted with a fluorine atom or alternatively with a chlorine atom or alternatively with a methoxy group,
as well as their isomers, pure or mixed, as well as their addition salts with a pharmaceutically acceptable acid, or a pharmaceutically acceptable base when R.sub.1 is a hydrogen atom.
Preferentially the invention relates to:
3-methyl-6-{4-(2-methoxyphenyl)-1-piperazinyl!methyl}benzoxazolinone, as well as its addition salts with a pharmaceutically acceptable acid,
3-methyl-6-{4-(2-methoxyphenyl)-1-piperazinyl!methyl}benzothiazolinone, as well as its addition salts with a pharmaceutically acceptable acid,
3-methyl-6-{4-(2-fluorophenyl)-1-piperazinyl!methyl}benzothiazolinone, as well as its addition salts with a pharmaceutically acceptable acid,
4-methyl-7-{4-(2-methoxyphenyl)-1 -piperazinyl!methyl}-3-oxo-3,4-dihydro-2H-1,4-benzoxazine, as well as its addition salts with a pharmaceutically acceptable acid,
3-methyl-6-{4-(2-fluorophenyl)-1-piperazinyl!methyl}benzoxazolinone, as well as its addition salts with a pharmaceutically acceptable acid,
4-methyl-7-{4-(2-fluorophenyl)-1 -piperazinyl!methyl}-3-oxo-3,4-dihydro-2H-1 ,4-benzoxazine, as well as its addition salts with a pharmaceutically acceptable acid,
3-methyl-6-{4-(4-chlorophenyl)-1-piperazinyl!methyl}benzoxazolinone, as well as its addition salts with a pharmaceutically acceptable acid,
3-methyl-6-{4-(4-chlorophenyl)-1-piperazinyl!methyl}benzothiazolinone, as well as its addition salts with a pharmaceutically acceptable acid,
6-{4-(2-fluorophenyl)-1-piperazinyl!methyl}benzoxazolinone, as well as its addition salts with a pharmaceutically acceptable acid or base,
6-{4-(2-fluorophenyl)-1-piperazinyl!methyl}benzothiazolinone, as well as its addition salts with a pharmaceutically acceptable acid or base,
4-methyl-7-{4-(4-chlorophenyl)-1 -piperazinyl!methyl}-3-oxo-3,4-dihydro-2H-1,4 benzoxazine, as well as its addition salts with a pharmaceutically acceptable acid,
3-{2-4-(4-fluorobenzoyl)-1-piperidyl!ethyl}-6-{4-(2-fluorophenyl)-1-piper azinyl!methyl}benzoxazolinone, as well as its addition salts with a pharmaceutically acceptable acid,
3-{2-4-(4',4'-difluorobenzhydrylidene)-1 -piperidyl!ethyl}-6-{4-(2-fluorophenyl)-1-piperazinyl!methyl}benzoxazolin one, as well as its addition salts with a pharmaceutically acceptable acid,
3-{2-4-(4-fluorobenzoyl)-1 -piperidyl!ethyl}-6-{4-(2-fluorophenyl)-1-piperazinyl!methyl}-benzothiazo linone, as well as its addition salts with a pharmaceutically acceptable acid,
4-methyl-7-{4-(benzod!-1,2-thiazolyl)-1 -piperazinyl!methyl}-3-oxo-3,4-dihydro-2H-1,4-benzoxazine, as well as its addition salts with a pharmaceutically acceptable acid,
3-methyl-6-{4-(benzod!-1,2-thiazolyl)-1-piperazinyl!methyl}benzoxazolinon e, as well as its addition salts with a pharmaceutically acceptable acid,
3-methyl-6-{4-(benzod!-1,2-thiazolyl)-1-piperazinyl!methyl}benzothiazolin one, as well as its addition salts with a pharmaceutically acceptable acid,
3-methyl-6-{4-(4-aminosulfonylphenyl)-1-piperazinyl!methyl}benzoxazolinone , as well as its addition salts with a pharmaceutically acceptable acid,
3-methyl-6-{4-(4-aminosulfonylphenyl)-1-piperazinyl!methyl}benzothiazolino ne, as well as its addition salts with a pharmaceutically acceptable acid,
4-methyl-7-{4-(4-aminosulfonylphenyl)-1 -piperazinyl!methyl}-3-oxo-3,4-dihydro-2H -1,4-benzoxazine, as well as its addition salts with a pharmaceutically acceptable acid,
3-methyl-6-{4-(3-methoxyphenyl)-1-piperazinyl!methyl}benzoxazolinone, as well as its addition salts with a pharmaceutically acceptable acid,
4-methyl-7-{4-(3-methoxyphenyl)-1 -piperazinyl!methyl}-3-oxo-3,4-dihydro-2H-1,4 -benzoxazine, as well as its addition salts with a pharmaceutically acceptable acid,
4-methyl-7-{4-(4-methoxyphenyl)-1-piperazinyl!methyl}-3-oxo-3,4-dihydro-2H -1,4-benzoxazine, as well as its addition salts with a pharmaceutically acceptable acid,
3-methyl-6-{4-(4-methoxyphenyl)-1-piperazinyl!methyl}benzothiazolinone, as well as its addition salts with a pharmaceutically acceptable acid,
3-methyl-6-{4-(4-methoxyphenyl)-1-piperazinyl!methyl}benzoxazolinone, as well as its addition salts with a pharmaceutically acceptable acid.
The invention also extends to the process for preparing the compounds of the formula (I), wherein
on the one hand, when, in the compound of formula (I) which it is desired to obtain, the group R.sub.1 represents a lower alkyl group, a compound of formula (II): ##STR11## in which A has the same meaning as above and R'.sub.1 represents a lower alkyl group is reacted with hexamethylenetetramine, preferably in an acid medium, to yield a product of formula (III): ##STR12## where R'.sub.1 and A have the same meaning as above which is treated with a hydrogenating agent to yield a product of formula (IV): ##STR13## where R'.sub.1 and A have the same meaning as above, on the other hand, when, in the compound of formula (I) which it is desired to obtain, R.sub.1 is other than a lower alkyl group, a compound of formula (V): ##STR14## where R.sub.a represents a lower alkyl group and A has the same meaning as above, is treated with a hydrogenating agent to obtain a compound of formula (IVb): ##STR15## where A has the same meaning as above, which compound of formula (IV) or (IVb) is treated with a halogenating agent to yield a product of formula (VI): ##STR16## where R".sub.1 represents a hydrogen atom or a lower alkyl group and A has the same meaning as above and Hal represents a halogen atom which is treated with an amine of formula (VII): ##STR17## where Y, n and Ar have the same meaning as in the formula (I) to obtain a product of formula (I/a) ##STR18## a special case of the compounds of formula (I) for which X represents a single bond, R".sub.1, A, Y, n and Ar having the same meaning as above which, when, in the product of formula (I) which it is desired to obtain, X represents a CH.sub.2 group, is treated with an alkaline agent to yield a compound of formula (VIII): ##STR19## where A, R".sub.1, Y, Ar and n have the same meaning as above which compound of formula VIII is treated with ethyl bromoacetate in an alkaline medium to yield a product of formula (I/b): ##STR20## a special case of the compounds of formula (I) for which X represents a CH.sub.2 group and R.sub.1 a lower alkyl group or a hydrogen atom and Y and Ar have the same meaning as above, which compound of formula I/a or I/b is, when, in the compound of formula (I) which it is desired to obtain, R.sub.1 represents neither a hydrogen atom nor a lower alkyl group, treated with a compound of formula (IX): ##STR21## where Hal represents a halogen atom and m and Ar.sub.1 have the same definition as in the formula (I) to yield a compound of formula I/c: ##STR22## a special case of the compounds of formula (I) for which R.sub.1 represents a group ##STR23## the compound of formula I/a, I/b or I/c thereby obtained being, where appropriate,
purified by one or more methods chosen from crystallization, chromatography, extraction and passage through resin or charcoal
separated, where appropriate, in pure form or in the form of a mixture, into its optical isomers,
and, if so desired, salified with a pharmaceutically acceptable acid, or a pharmaceutically acceptable base.
The compounds of formula III, IV, IVb and VI are new and, as such, form part of the invention in the same way as the compounds of formula (I) for which they constitute synthesis intermediates, with the exception of the compound of formula III for which A represents an oxygen atom and R'.sub.1 a methyl group (Renard et al.; Bull. Soc. Pharm. Lille, 1979, 2-3, 125-138). More especially, among these compounds, the following are preferred:
3-methyl-6-formylbenzothiazolinone,
3-methyl-6-(hydroxymethyl)benzoxazolinone,
3-methyl-6-(hydroxymethyl)benzothiazolinone,
6-(hydroxymethyl)benzoxazolinone,
6-(hydroxymethyl)benzothiazolinone,
the 3-methyl-6-(halomethyl)benzoxazolinones,
the 3-methyl-6-(halomethyl)benzothiazolinones,
the 6-(halomethyl)benzoxazolinones,
the 6-(halomethyl)benzothiazolinones.
The compounds of formula VIII are also new and also form part of the invention in the same way as the compounds of formula (I) for which they constitute synthesis intermediates, as well as their possible isomers and the addition salts with a pharmaceutically acceptable acid or base.
The compounds of formula (I) possess advantageous pharmacological properties.
Binding tests showed that the compounds of the invention behave as very potent D.sub.4 receptor ligands. This affinity is accompanied by a very great selectivity with respect to the other receptors, in particular D.sub.2. This is all the more surprising for the fact that the compounds of the prior art mentioned above do not have affinity for the D.sub.4 receptor but possess, in contrast, a high affinity for the D.sub.2 receptors.
The compounds of the invention are of low toxicity and, as a result of their receptor profile, should possess good activity in schizophrenia and in various categories of psychoses, in the modulation of mood and of the cognitive functions, in anxiety, depression, drug abuse, impulsive states and mnemocognitive disorders, as well as migrainous states.
The subject of the present invention is also pharmaceutical compositions containing as active principle at least one compound of general formula (I) or one of its addition salts with a pharmaceutically acceptable acid or, where appropriate, with a pharmaceutically acceptable base, alone or in combination with one or more inert, nontoxic excipients or vehicles.
Among the pharmaceutical compositions according to the invention, there may be mentioned, more especially, those which are suitable for oral, parenteral or nasal administration, simple or sugar-coated tablets, sublingual tablets, sachets, packets, hard gelatin capsules, preparations to be dissolved under the tongue, lozenges, suppositories, creams, ointments, skin gels, and the like.
The dosage varies according to the patient's age and weight, the nature and severity of the disorder and also the administration route. The latter can be oral, nasal, rectal or parenteral.
Generally speaking, the unit dosage ranges between 0.05 mg and 30 mg for disorders of mental behavior, in one to three doses per 24 hours.
The examples which follow illustrate the invention and in no way limit it.
.sup.1 H nuclear magnetic resonance spectra were carried out using TMS (tetramethylsilane) as internal reference. Chemical shifts are expressed in parts per million (ppm). Infrared spectra were recorded in the form of a potassium bromide disk containing approximately 1% of the product to be analyzed.
Except where otherwise stated, the preparations do not form part of the invention but are useful for carrying out the synthesis of the compounds of the invention.
Preparation 1: 3-METHYLBENZOTHIAZOLINONE
1 mol of sodium hydroxide is dissolved in 2000 cm.sup.3 of water, 1 mol of benzothiazolinone is added and 1 mol of methyl sulfate is then added dropwise. The mixture is stirred for 3 hours with magnetic stirring at room temperature. The product is drained, washed with water, dried and recrystallized in 2-propanol.
Molar mass: 165.21 g.mol.sup.-1 for C.sub.8 H.sub.7 NOS
Melting point: 74.degree. C.
Yield: 76%
Rf: 0.7 Eluent: cyclohexane/toluene/acetone (5:2:3)
Infrared spectrometry
2940-2910 cm-.sup.-1 .nu.CH
1680 cm.sup.-1 .nu.CO--S
1580 cm.sup.-1 .nu.C.dbd.C
______________________________________
Nuclear magnetic resonance spectrometry (80 MHz, DMSO-d.sub.6)
______________________________________
.delta.: 3.45 ppm
singlet 3H N--CH.sub.3
.delta.: 7.30 ppm
complex 4H aromatic
______________________________________
Preparation 2: 3-METHYLBENZOXAZOLINONE
With magnetic stirring, 1 mol of sodium hydroxide and 1 mol of benzoxazolinone are dissolved in 2000 cm.sup.3 of water and 1 mol of methyl sulfate is then added dropwise. Stirring is continued for 3 hours. The precipitate obtained is filtered off and washed with 1% aqueous sodium hydroxide solution (2 times 200 cm.sup.3) and then with water until the washing liquors are neutral. The product is dried and recrystallized in 95.degree. strength alcohol.
Molar mass: 149.15 g.mol.sup.-1 for C.sub.8 H.sub.7 NO.sub.2
Melting point: 86.degree. C.
Yield: 76%
Rf: 0.9 Eluent: methanol (saturated with ammonia)/chloroform (1:9)
Infrared spectrometry
3050 cm.sup.-1 .nu.CH
1760 cm.sup.-1 .nu.CO-O
1590 cm.sup.-1 .nu.C.dbd.C
______________________________________
Nuclear magnetic resonance spectrometry (80 MHz, DMSO-d.sub.6)
______________________________________
.delta.: 3.35 ppm
singlet 3H N--CH.sub.3
.delta.: 7.40 ppm
complex 4H aromatic
______________________________________
Preparation 3: 3-METHYL-6-FORMYLBENZOTHIAZOLINONE
0.010 mol of 3-methylbenzothiazolinone and 0.015 mol of hexamethylene tetramine are crushed in a mortar, and the two products are then introduced successively into a round-bottomed flask containing 50 g of polyphosphoric acid at 130.degree. C., with mechanical stirring in an oil bath. The reaction mixture is heated to 130.degree. C. for 20 minutes. After cooling, it is poured into 300 cm.sup.3 of ice-cold water. The mixture is stirred for 1 hour. The precipitate is drained, washed with water and dried. The filtrate is extracted 3 times with 30 cm.sup.3 of chloroform. The chloroform phases are washed with water, dried over calcium chloride and evaporated under reduced pressure. The product is dried and recrystallized in absolute ethanol.
Molar mass: 193.22 g.mol.sup.-1 for C.sub.9 H.sub.7 NO.sub.2 S
Melting point: 135.degree. C.
Yield: 73%
Rf: 0.8 Eluent: cyclohexane/toluene/acetone (5:2:3)
Infrared spectrometry
1680 cm.sup.-1 .nu.CO-S and .nu.CO
1590 cm.sup.-1 .nu.C.dbd.C
______________________________________
Nuclear magnetic resonance spectrometry (80 MHz, DMSO-d.sub.6)
______________________________________
.delta.: 3.45 ppm
singlet 3H N--CH.sub.3
.delta.: 7.50 ppm
doublet 1H H.sub.4
J.sub.4-5 = 8.30 Hz
.delta.: 7.80 ppm
doublet of doublets
1H H.sub.5
J.sub.5-4 = 8.30 Hz
J.sub.5-7 = 1.30 Hz
.delta.: 8.20 ppm
doublet 1H H.sub.7
J.sub.7-5 = 1.30 Hz
.delta.: 9.90 ppm
singlet 1H CHO
______________________________________
Note: This compound (Preparation 3) forms part of the invention in the
same way as the compounds of formula (I).
Preparation 4: 3-METHYL-6-FORMYLBENZOXAZOLINONE
0.10 mol of 3-methylbenzoxazolinone and 0.15 mol of hexamethylenetetramine are mixed in a mortar. The mixture is introduced into a round-bottomed flask containing 200 g of polyphosphoric acid at 90.degree. C., with stirring in an oil bath. The reaction mixture is heated to 150.degree. C. for 10 minutes while stirring. After cooling, it is poured into 500 cm.sup.3 of ice-cold water and stirred for one hour. The precipitate obtained is drained, washed with water and dried. The filtrate is subjected to several extractions with chloroform. The combined chloroform phases are washed with water, dried over calcium chloride and evaporated under reduced pressure. The product obtained, combined with the above precipitate, is recrystallized in water.
Molar mass: 177.16 g.mol.sup.-1 for C.sub.9 H.sub.7 NO3
Melting point: 146.degree. C.
Yield: 74%
Rf: 0.8 Eluent: methanol (saturated with ammonia)/chloroform (1:9)
Infrared spectrometry
3040 cm.sup.-1 .nu.CH
1765 cm.sup.-1 .nu.CO-O
1675 cm.sup.-1 .nu.CO
1600 cm.sup.-1 .nu.C.dbd.C
______________________________________
Nuclear magnetic resonance spectrometry (300 MHz, DMSO-d.sub.6)
______________________________________
.delta.: 3.40 ppm
singlet 3H N--CH.sub.3
.delta.: 7.50 ppm
doublet 1H H.sub.4
J.sub.4-5 = 8.30 Hz
.delta.: 7.80 ppm
doublet of doublets
1H H.sub.5
J.sub.5-4 = 8.30 Hz
J.sub.5-7 = 1.30 Hz
.delta.: 8.00 ppm
doublet 1H H.sub.7
J.sub.7-5 = 1.30 Hz
.delta.: 9.80 ppm
singlet 1H CHO
______________________________________
Preparation 5: 3-METHYL-6-(HYDROXYMETHYL)BENZOTHIAZOLINONE
0.010 mol of 3-methyl-6-formylbenzothiazolinone is introduced at room temperature into 50 cm.sup.3 of methanol. 0.015 mol of sodium borohydride is added in small portions with magnetic stirring. After 2 hours of stirring at room temperature, the methanol is evaporated off under reduced pressure and the residue is then taken up with 50 cm.sup.3 of water. The precipitate is drained, dried and then recrystallized in 2-propanol.
Molar mass: 195.24 g.mol.sup.-1 for C.sub.9 H.sub.9 NO.sub.2 S
Melting point: 120.degree. C.
Yield: 79%
Rf: 0.5 Eluent: cyclohexane/toluene/acetone (5:2:3)
Infrared spectrometry
3350 cm.sup.-1 .nu.OH
2960-2800 cm.sup.-1 .nu.CH
1670 cm.sup.-1 .nu.CO--S
1600 cm.sup.-1 .nu.C.dbd.C
______________________________________
Nuclear magnetic resonance spectrometry (80 MHz, DMSO-d.sub.6)
______________________________________
.delta.: 3.40 ppm
singlet 3H N--CH.sub.3
.delta.: 4.50 ppm
singlet 2H CH.sub.2
.delta.: 5.25 ppm
signal 1H OH exchangeable with D.sub.2 O
.delta.: 7.30 ppm
complex 2H H.sub.4, H.sub.5
.delta.: 7.60 ppm
singlet 1H H.sub.7
______________________________________
Note: This compound (Preparation 5) forms part of the invention in the
same way as the compounds of formula (I).
Preparation 6: 3-METHYL-6-HYDROXYMETHYLBENZOXAZOLINONE
0.10 mol of 3-methyl-6-formylbenzoxazolinone is introduced into 150 cm.sup.3 of methanol. 0.15 mol of sodium borohydride is added in small portions at room temperature with magnetic stirring. After 2 hours, the methanol is evaporated off under reduced pressure and the residue is taken up with water. The precipitate is drained and then recrystallized in water.
Molar mass: 179.17 g.mol.sup.-1 for C.sub.9 H.sub.9 NO.sub.3
Melting point: 127.degree. C.
Yield: 73%
Rf: 0.5 Eluent: methanol (saturated with ammonia)/chloroform (1:9)
Infrared spectrometry
3500-3200 cm.sup.-1 .nu.OH
3080-2880 cm.sup.-1 .nu.CH
1755 cm.sup.-1 .mu.CO--O
1620 cm.sup.-1 .mu.C.dbd.C
______________________________________
Nuclear magnetic resonance spectrometry (80 MHz, DMSO-d.sub.6)
______________________________________
.delta.: 3.35 ppm
singlet 3H N--CH.sub.3
.delta.: 4.55 ppm
singlet 2H CH.sub.2
.delta.: 5.25 ppm
signal 1H OH exchangeable with D.sub.2 O
.delta.: 7.20 ppm
complex 2H H.sub.4, H.sub.5
.delta.: 7.25 ppm
singlet 1H H.sub.7
______________________________________
Note: This compound (Preparation 6) forms part of the invention in the
same way as the compounds of formula (I).
Preparaion 7: 6-HYDROXYMETHYLBENZOXAZOLINONE
0.01 mol of 6-(ethoxycarbonyl)benzoxazolinone and 0.03 mol of lithium aluminum hydride in small portions are introduced into 50 cm.sup.3 of tetrahydrofuran cooled in an ice bath. The mixture is stirred at room temperature for one hour. It is hydrolyzed in 100 cm.sup.3 of ice-cold water acidified to pH 1 with 6N hydrochloric acid. The product is extacted with three times 50 cm.sup.3 of chloroform, and the organic phase is dried and then evaporated. The compound is dried and recrystallized in acetonitrile.
Molar mass: 165.14 g.mol.sup.-1 for C.sub.8 H.sub.7 NO.sub.3
Melting point: 153.degree.-154.degree. C.
Yield: 48%
Rf: 0.2 Eluent:methanol (saturated with ammonia)/chloroform (1:9)
Infrared spectrometry
3330 cm.sup.-1 .nu.OH and .nu.NH
3100-2700 cm.sup.-1 .nu.CH
1740 cm.sup.-1 .nu.CO--O
1620 cm.sup.-1 .nu.C.dbd.C
______________________________________
Nuclear magnetic resonance spectrometry (80 MHz, DMSO-d.sub.6)
______________________________________
.delta.: 4.60 ppm
singlet 2H CH.sub.2
.delta.: 5.30 ppm
signal 1H OH exchangeable with D.sub.2 O
.delta.: 7.00 ppm
complex 2H H.sub.4, H.sub.5
.delta.: 7.30 ppm
singlet 1H H.sub.7
.delta.: 11.60 ppm
singlet 1H NH exchangeable with D.sub.2 O
______________________________________
Note: This compound (Preparation 7) forms part of the invention in the
same way as the compounds of formula (I).
Preparation 8: 3-METHYL-6-(CHLOROMETHYL)BENZOTHIAZOLINONE
0.01 mol of 3-methyl-6-(hydroxymethyl)benzothiazolinone is introduced into 50 cm.sup.3 of chloroform. 0.02 mol of thionyl chloride is added dropwise by means of a dropping funnel. The mixture is brought to reflux for 4 hours. The chloroform is evaporated off under reduced pressure, and the residue is then taken up 3 times with absolute ethanol in order to eliminate the traces of thionyl chloride. The product is dried and recrystallized in 2-propanol.
Molar mass: 213.68 g.mol.sup.-1 for C.sub.9 H.sub.8 CINOS
Melting point: 128.degree. C.
Yield: 95%
Rf: 0.8 Eluent: cyclohexane/toluene/acetone (5:2:3)
Infrared spectrometry
1680 cm.sup.-1 .nu.CO--S
1600 cm.sup.-1 .nu.C.dbd.C
______________________________________
Nuclear magnetic resonance spectrometry (300 MHz, DMSO-d.sub.6)
______________________________________
.delta.: 3.40 ppm
singlet 3H N--CH.sub.3
.delta.: 4.80 ppm
singlet 2H CH.sub.2
.delta.: 7.25 ppm
doublet 1H H.sub.4
J.sub.4-5 = 8.30 Hz
.delta.: 7.45 ppm
doublet of doublets
1H H.sub.5
J.sub.5-4 = 8.30 Hz
J.sub.5-7 = 1.30 Hz
.delta.: 7.75 ppm
doublet 1H H.sub.7
J.sub.7-5 = 1.30 Hz
______________________________________
Note: This compound (Preparation 8) forms part of the invention in the
same way as the compounds of formula (I).
Preparation 9: 3-METHYL-6-(CHLOROMETHYL)BENZOXAZOLINONE
0.10 mol of 3-methyl-6-(hydroxymethyl)benzoxazolinone is dissolved in 100 cm.sup.3 of chloroform. 0.20 mol of thionyl chloride is added dropwise by means of a dropping funnel. The mixture is brought to reflux for 4 hours. The chloroform is evaporated off under reduced pressure, and the residue is then taken up 3 times with absolute ethanol in order to eliminate the traces of thionyl chloride. The product is dried and then recrystallized in 2-propanol.
Molar mass: 197.62 g.mol.sup.-1 for C.sub.9 H.sub.8 CINO.sub.2
Melting point: 132.5.degree. C.
Yield: 84%
Rf: 0.8 Eluent: methanol (saturated with ammonia)/chloroform (1:9)
Infrared spectrometry
3040 cm.sup.-1 .nu.CH
1755 cm.sup.-1 .nu.CO--O
1610 cm.sup.-1 .nu.C.dbd.C
______________________________________
Nuclear magnetic resonance spectrometry (80 MHz, DMSO-d.sub.6)
______________________________________
.delta.: 3.35 ppm
singlet 3H N--CH.sub.3
.delta.: 4.80 ppm
singlet 2H CH.sub.2
.delta.: 7.30 ppm
complex 2H H.sub.4, H.sub.5
.delta.: 7.45 ppm
singlet 1H H.sub.7
______________________________________
Note: This compound (Preparation 9) forms part of the invention in the
same way as the compounds of formula (I).
Preparation 10: 6-(CHLOROMETHYL)BENZOXAZOLINONE
0.01 mol of 6-(hydroxymethyl)benzoxazolinone is introduced into 50 cm.sup.3 of chloroform. 0.02 mol of thionyl chloride is added dropwise by means of a dropping funnel. The mixture is brought to reflux for 2 hours. The chloroform is evaporated off under reduced pressure, and the residue is then taken up 3 times with absolute ethanol in order to eliminate the traces of thionyl chloride. The product is dried and recrystallized in 2-propanol.
Molar mass: 183.59 g.mol.sup.-1 for C.sub.8 H.sub.6 CINO.sub.2
Melting point: 186-187.degree. C.
Yield: 72%
Rf: 0.5 Eluent: methanol (saturated with ammonia)/chloroform (1:9)
Infrared spectrometry
3200 cm.sup.-1 .nu.NH
1760 cm.sup.-1 .nu.CO--O
1610 cm.sup.-1 .nu.C.dbd.C
______________________________________
Nuclear magnetic resonance spectrometry (80 MHz, DMSO-d.sub.6)
______________________________________
.delta.: 4.80 ppm
singlet 2H CH.sub.2
.delta.: 7.20 ppm
complex 3H H.sub.4, H.sub.5, H.sub.7
.delta.: 11.75 ppm
singlet 1H NH exchangeable with D.sub.2 O
______________________________________
Note: This compound (Preparation 10) forms part of the invention in the
same way as the compounds of formula (I).
Preparation 11: 6-HYDROXYMETHYLBENZOTHIAZOLINONE
0.01 mol of 6-(ethoxycarbonyl)benzothiazolinone and 0.03 mol of lithium aluminum hydride in small portions are introduced into 50 cm.sup.3 of tetrahydrofuran cooled in an ice bath. The mixture is stirred at room temperature for 30 minutes. It is hydrolyzed in 100 cm.sup.3 of ice-cold water acidified to pH 1 with 6N hydrochloric acid. The product is extracted with 3 times 50 cm.sup.3 of chloroform, and the organic phase is dried and then evaporated. The compound is dried and recrystallized in acetonitrile.
Molar mass: 181.21 g.mol.sup.-1 for C.sub.8 H.sub.7 NO.sub.2 S
Melting point: 168-170.degree. C.
Yield: 40 %
Rf: 0.2 Eluent: methanol (saturated with ammonia)/chloroform (1:9)
Infrared spectrometry
3300 cm.sup.-1 .nu.OH and .nu.NH
3000-2800 cm.sup.-1 .nu.CH
1650 cm.sup.-1 .nu.CO--S
______________________________________
Nuclear magnetic resonance spectrometry (300 MHz, DMSO-d.sub.6)
______________________________________
.delta.: 4.50 ppm
singlet 2H CH.sub.2
.delta.: 5.20 ppm
signal 1H OH exchangeable with D.sub.2 O
.delta.: 7.10 ppm
doublet 1H H.sub.4
J.sub.4-5 = 8.00 Hz
.delta.: 7.25 ppm
doublet 1H H.sub.5
J.sub.5-4 = 8.00 Hz
.delta.: 7.50 ppm
singlet 1H H.sub.7
.delta.: 11.85 ppm
singlet 1H NH exchangeable with D.sub.2 O
______________________________________
Note: This compound (Preparation 11) forms part of the invention in the
same way as the compounds of formula (I).
Preparation 12: 6-(CHLOROMETHYL)BENZOTHIAZOLINONE
0.01 mol of 6-(hydroxymethyl)benzothiazolinone is introduced into 50 cm.sup.3 of chloroform, and 0.02 mol of thionyl chloride is added dropwise by means of a dropping funnel. The mixture is brought to reflux for 2 hours. The chloroform is evaporated off under reduced pressure, and the residue is then taken up 3 times with absolute ethanol in order to eliminate the traces of thionyl chloride. The product is dried and recrystallized in toluene.
Molar mass: 199.66 g.mol.sup.31 1 for C.sub.8 H.sub.6 CINOS
Melting point: 183-184.degree. C.
Yield: 73%
Rf: 0.6 Eluent: methanol (saturated with ammonia)/chloroform (1:9)
Infrared spectrometry
3140 cm.sup.-1 .nu.NH
3080-2820 cm.sup.-1 .nu.CH
1660 cm.sup.-1 .nu.CO--S
1600 cm.sup.-1 .nu.C.dbd.C
______________________________________
Nuclear magnetic resonance spectrometry (300 MHz, DMSO-d.sub.6)
______________________________________
.delta.: 4.80 ppm
singlet 2H CH.sub.2
.delta.: 7.10 ppm
doublet 1H H.sub.4
J.sub.4-5 = 8.25 Hz
.delta.: 7.50 ppm
doublet 1H H.sub.5
J.sub.5-4 = 8.25 Hz
.delta.: 7.65 ppm
singlet 1H H.sub.7
.delta.: 12.00 ppm
singlet 1H NH exchangeable with D.sub.2 O
______________________________________
Note: This compound (Preparation 12) forms part of the invention in the
same way as the compounds of formula (I).
EXAMPLE 1
3-METHYL-6-(4-(2-METHOXYPHENYL)-1-PIPERAZINYL)METHYL!-BENZOTHIAZOLINONE HYDROCHLORIDE
0.01 mol of 3-methyl-6-(chloromethyl)benzothiazolinone, 0.012 mol of N-(orthomethoxyphenyl)piperazine hydrochloride and 0.022 mol of triethylamine are added to 20 cm.sup.3 of dioxane. The mixture is heated to reflux with magnetic stirring for 6 days. The inorganic residue is filtered off and the dioxane is then evaporated off under reduced pressure. The residue is taken up with 50 cm.sup.3 of water, then filtered off and dried. The product is dissolved in the minimum of absolute ethanol, and 100 cm.sup.3 of absolute ethanol saturated with gaseous hydrochloric acid are added. The precipitate is filtered off, washed with absolute ethanol, dried and then recrystallized in methanol.
Molar mass: 405.95 g.mol.sup.-1 for C.sub.20 H.sub.24 CIN.sub.3 O.sub.2 S
Melting point: 168.degree. C.
Yield: 33%
Rf: 0.8 Eluent: cyclohexane/toluene/acetone (5:2:3)
Infrared spectrometry
3060-2840 cm.sup.-1 .nu.CH
15 2640-2060 cm.sup.-1 .nu.NH.sup.+
1670 cm.sup.-1 .nu.CO--S
1600 cm.sup.-1 .nu.C.dbd.C
______________________________________
Nuclear magnetic resonance spectrometry (300 MHz, DMSO-d.sub.6)
______________________________________
.delta.: 3.00 ppm
complex 4H piperazine
.delta.: 3.40 ppm
complex 4H piperazine
.delta.: 3.45 ppm
singlet 3H N--CH.sub.3
.delta.: 3.80 ppm
singlet 3H O--CH.sub.3
.delta.: 4.40 ppm
singlet 2H CH.sub.2
.delta.: 7.00 ppm
complex 4H phenyl
.delta.: 7.45 ppm
doublet 1H H.sub.4
J.sub.4-5 = 8.30 Hz
.delta.: 7.65 ppm
doublet 1H H.sub.5
J.sub.5-4 = 8.30 Hz
.delta.: 7.90 ppm
singlet 1H H.sub.7
.delta.: 11.00 ppm
signal 1H NH.sup.+
exchangeable with D.sub.2 O
______________________________________
EXAMPLE 2
3-METHYL-6-(4-(2-METHOXYPHENYL)-1-PIPERAZINYL)-METHYL!BENZOXAZOLINONE HYDROCHLORIDE
0.010 mol of 3-methyl-6-(chloromethyl)benzoxazolinone, 0.020 mol of triethylamine, 0.012 mol of N-(ortho-methoxyphenyl)piperazine and 0.001 mol of potassium iodide are added to 50 cm.sup.3 of acetone. The mixture is heated to reflux with magnetic stirring for 4 days. The inorganic residue is filtered off and the filtrate is then evaporated to dryness under reduced pressure. 20 cm.sup.3 of 1N hydrochloric acid and 30 cm.sup.3 of ethyl acetate are added. The mixture is left stirring for 30 minutes. The precipitate is filtered off, washed several times with ethyl acetate, dried and then recrystallized in methanol.
Molar mass: 389.88 g.mol.sup.-1 for C.sub.20 H.sub.24 CIN.sub.3 O.sub.3
Melting point: >260.degree. C. (hydrochloride form)
Melting point:: 149-150.degree. C. (base form)
Yield: 52%
Rf: 0.8 Eluent: methanol (saturated with ammonium)/chloroform (1:9)
Infrared spectrometry
3060-2820 cm.sup.-1 .nu.CH
2700-2300 cm.sup.-1 .nu.NH+
1780 cm.sup.-1 .nu.CO--O
1610 cm.sup.-1 .nu.C.dbd.C
1590 cm.sup.-1 .nu.C.dbd.C
______________________________________
Nuclear magnetic resonance spectrometry (300 MHz, DMSO-d.sub.6)
______________________________________
.delta.: 3.05 ppm
complex 4H piperazine
.delta.: 3.40 ppm
complex 7H N--CH.sub.3,
piperazine
.delta.: 3.80 ppm
singlet 3H O--CH.sub.3
.delta.: 4.40 ppm
singlet 2H CH.sub.2
.delta.: 6.95 ppm
complex 4H phenyl
.delta.: 7.40 ppm
doublet 1H H.sub.4
J.sub.4-5 = 8.00 Hz
.delta.: 7.50 ppm
doublet 1H H.sub.5
J.sub.5-4 = 8.00 Hz
.delta.: 7.65 ppm
singlet 1H H.sub.7
.delta.: 11.45 ppm
signal 1H NH.sup.+
exchangeable with D.sub.2 O
______________________________________
EXAMPLE 3
3-METHYL-6-(4-(2-FLUOROPHENYL)-1-PIPERAZINYL)METHYL!-BENZOTHIAZOLINONE
0.01 mol of 3-methyl-6-(chloromethyl)benzothiazolinone, 0.01 fluoroph-(orthofluorophenyl)piperazine and 0.01 mol of triethylamine are added to 20 cm.sup.3 of dioxane. The mixture is heated to reflux with magnetic stirring for 3 days. The inorganic residue is filtered off and the dioxane is then evaporated off under reduced pressure. The residue is taken up with 50 cm.sup.3 of water, then filtered off, dried and recrystallized in 1-propanol.
Molar mass: 357.45 g.mol.sup.-1 for C.sub.19 H.sub.20 FN.sub.3 OS
Melting point: 152.degree. C.
Yield: 60%
Rf: 0.8 Eluent: cyclohexane/toluene/acetone (5:2:3)
Infrared spectrometry
2960-2760 cm.sup.-1 .nu.CH
1670 cm.sup.-1 .nu.CO--S
1600 cm.sup.-1 .nu.C.dbd.C
______________________________________
Nuclear magnetic resonance spectrometry (300 MHz, DMSO-d.sub.6)
______________________________________
.delta.:3.00 ppm
complex 4H piperazine
.delta.:3.35 ppm
complex 4H piperazine
.delta.:3.40 ppm
singlet 3H N--CH.sub.3
.delta.:3.55 ppm
singlet 2H CH.sub.2
.delta.:7.00 ppm
complex 4H phenyl
.delta.:7.25 ppm
doublet 1H H.sub.4 J.sub.4-5 = 8.25 Hz
.delta.:7.35 ppm
doublet 1H H.sub.5 J.sub.5-4 = 8.25 Hz
.delta.:7.65 ppm
singlet 1H H.sub.7
______________________________________
EXAMPLE 4
3-METHYL-6-(4-(2-FLUOROPHENYL)-1 -PIPERAZINYL)METHYL!BENZOXAZOLINONE HYDROCHLORIDE
The procedure is identical to that described for obtaining Example 2, replacing N-(ortho-methoxyphenyl)piperazine by N-(ortho-fluorophenyl)piperazine.
Reaction time: 3 days
Molar mass: 377.84 g.mol.sup.-1 for C.sub.19 H.sub.21 CIFN.sub.3 O.sub.2
Melting point: >260.degree. C. (hydrochloride form)
Melting point: 134-135.degree. C. (base form)
Yield: 50%
Recrystallization solvent: methanol
Rf: 0.8 Eluent: methanol (saturated with ammonia)/chloroform (1:9)
Infrared spectrometry
3040-2820 cm.sup.-1 .nu.CH
2740-2320 cm.sup.-1 .nu.NH.sup.+
1770 cm.sup.-1 .nu.CO--O
1610 cm.sup.-1 .nu.C.dbd.C
______________________________________
Nuclear magnetic resonance spectrometry (300 MHz, DMSO-d.sub.6)
______________________________________
.delta.: 3.15 ppm
complex 4H piperazine
.delta.: 3.20 ppm
singlet 3H N--CH.sub.3
.delta.: 3.50 ppm
complex 4H piperazine
.delta.: 4.40 ppm
singlet 2H CH.sub.2
.delta.: 7.10 ppm
complex 4H phenyl
.delta.: 7.40 ppm
multiplet
1H H.sub.4
.delta.: 7.45 ppm
multiplet
1H H.sub.5
.delta.: 7.65 ppm
singlet 1H H.sub.7
.delta.: 11.05 ppm
signal 1H NH.sup.+ exchangeable with D.sub.2 O
______________________________________
EXAMPLE 5
3-METHYL-6-(4-(4-CHLOROPHENYL)-1-PIPERAZINYL)METHYL!-BENZOTHIAZOLINONE
The procedure is identical to that described for obtaining Example 2, replacing N-(ortho-methoxyphenyl)piperazine by N-(para-chlorophenyl)piperazine and 3-methyl-6-(chloromethyl)benzoxazolinone by 3-methyl-6-(chloromethyl)benzothiazolinone. The product in hydrochloride form is obtained in base form in ethyl acetate in the presence of triethylamine.
Reaction time: 2 days
Molar mass: 373.90 g.mol.sup.-1 for C.sub.19 H.sub.20 CIN.sub.3 OS
Melting point: 162-163.degree. C.
Yield: 45%
Recrystallization solvent: methanol
Rf: 0.7 Eluent: methanol (saturated with ammonia/chloroform (1:9)
Infrared spectrometry
2960-2740 cm.sup.-1 .nu.CH
1660 cm.sup.-1 .nu.CO--S
1590 cm.sup.-1 .nu.C.dbd.C
______________________________________
Nuclear magnetic resonance spectrometry (300 MHz, DMSO-d.sub.6)
______________________________________
.delta.: 2.50 ppm
complex 4H piperazine
.delta.: 3.10 ppm
complex 4H piperazine
.delta.: 3.40 ppm
singlet 3H N--CH.sub.3
.delta.: 3.55 ppm
singlet 2H CH.sub.2
.delta.: 6.90 ppm
complex 2H H.sub.4, H.sub.5
.delta.: 7.30 ppm
complex 4H phenyl
.delta.: 7.60 ppm
singlet 1H H.sub.7
______________________________________
EXAMPLE 6
3-METHYL-6-(4-(4-CHLOROPHENYL)-1-PIPERAZINYL)METHYL!-BENZOXAZOLINONE
The procedure is identical to that described for obtaining Example 2, replacing N-(ortho-methoxyphenyl)piperazine by N-(para-chlorophenyl)piperazine. The product in hydrochloride form is converted to base form in ethyl acetate in the presence of triethylamine.
Reaction time: 3 days
Molar mass: 357.84 g.mol.sup.-1 for C.sub.19 H.sub.20 CIN.sub.3 O.sub.2
Melting point: 165-166.degree. C.
Yield: 65%
Recrystallization solvent: methanol
Rf: 0.8 Eluent: methanol (saturated with ammonia)/chloroform (1:9)
Infrared spectrometry
2960-2740 cm.sup.-1 .nu.CH
1760 cm.sup.-1 .nu.CO--O
1615 cm.sup.-1 .nu.C.dbd.C
1590 cm.sup.-1 .nu.C.dbd.C
______________________________________
Nuclear magnetic resonance spectrometry (300 MHz, DMSO-d.sub.6)
______________________________________
.delta.: 2.50 ppm
complex 4H piperazine
.delta.: 3.10 ppm
complex 4H piperazine
.delta.: 3.35 ppm
singlet 3H N--CH.sub.3
.delta.: 3.55 ppm
singlet 2H CH.sub.2
.delta.: 6.90 ppm
complex 2H H.sub.4, H.sub.5
.delta.: 7.20 ppm
complex 4H phenyl
.delta.: 7.30 ppm
singlet 1H H.sub.7
______________________________________
EXAMPLE 7
4-METHYL-7-(4-(2-METHOXYPHENYL)-1-PIPERAZINYL)METHYL!-3-OXO-3,4-DIHYDRO-2H -1,4BENZOXAZINE
Stage A: 5-(4-(2-METHOXYPHENYL)-1-PIPERAZINYL)METHYL!-2-(METHYLAMINO)PHENOL
Note: This compound forms part of the invention in the same way as Example 7.
0.08 mol of sodium hydroxide is dissolved in 5 cm.sup.3 of water, and 25 cm.sup.3 of methanol and 0.01 mol of 3-methyl-6-(4-(ortho-methoxyphenyl)-1-piperazinyl)methyl!benzoxazolinone hydrochloride are then added. The mixture is heated to reflux with magnetic stirring for 2 hours. The methanol is evaporated off under reduced pressure and the residue is then dissolved in 50 cm.sup.3 of water. The solution is placed in a bath of ice-cold water, 6N hydrochloric acid is added until the pH=1, and the mixture is then alkalinized with 10% aqueous potassium carbonate solution until the pH=8-9. The mixture is stirred for 30 minutes. The precipitate is filtered off, washed with water until the washing liquors are neutral, dried and then recrystallized in toluene.
Molar mass: 363.88 g.mol.sup.-1 for C.sub.19 H.sub.26 CIN.sub.3 O.sub.2
Melting point: 155-156.degree. C.
Yield: 67%
Rf: 0.7 Eluent: methanol (saturated with ammonia)/chloroform (1:9)
Infrared spectrometry
3500 cm.sup.-1 .nu.OH
3180 cm.sup.-1 .nu.NH
2980-2800 cm.sup.-1 .nu.CH
2720-2520 cm.sup.-1 .nu.NH.sup.+
1620 cm.sup.-1 .nu.C.dbd.C
1590 cm.sup.-1 .nu.C.dbd.C
______________________________________
Nuclear magnetic resonance spectrometry (300 MHz, DMSO-d.sub.6)
______________________________________
.delta.: 2.75 ppm
singlet 3H N--CH.sub.3
.delta.: 3.10 ppm
complex 4H piperazine
.delta.: 3.40 ppm
singlet 4H piperazine
.delta.: 3.80 ppm
singlet 3H O--CH.sub.3
.delta.: 4.10 ppm
singlet 2H CH.sub.2
.delta.: 5.10 ppm
signal 1H OH exchangeable with D.sub.2 O
.delta.: 6.40 ppm
doublet 1H H.sub.3 J3.sub.-4 = 7.95 Hz
.delta.: 6.95 ppm
complex 6H H.sub.4, H.sub.6 and phenyl
.delta.: 9.60 ppm
singlet 1H NH exchangeable with D.sub.2 O
.delta.: 10.80 ppm
signal 1H NH* exchangeable with D.sub.2 O
______________________________________
Stage B: 4-METHYL-7-(4-(2-METHOXYPHENYL)-1 -PlPERAZINYL)METHYL!-3-OXO-3,4-DIHYDRO-2H-1,4-BENZOXAZINE
0.01 mol of sodium is dissolved in 40 cm.sup.3 of absolute ethanol. The absolute ethanol is evaporated off, and 20 cm.sup.3 of dimethyl sulfoxide and 0.01 mol of 5-(4-(orthomethoxyphenyl)-1-piperazinyl)methyl!-2-(methylamino)phenol are then added. The mixture is stirred for 30 minutes, 0.01 mol of ethyl bromoacetate is added and the mixture is then left for 16 hours at room temperature with magnetic stirring. It is hydrolyzed in 100 cm.sup.3 of ice-cold water, and the solution is acidified with 1N hydrochloric acid until the pH=1 and then alkalinized with 10% aqueous potassium carbonate solution until the pH=8-9. The product is extracted 3 times with 30 cm.sup.3 of ethyl acetate. The organic phase is washed with water, dried over magnesium sulfate and then evaporated under reduced pressure. The residue is washed with ether, the mixture is then filtered and the ether is evaporated off under reduced pressure. The product is dried and recrystallized in absolute ethanol.
Molar mass: 367.44 g.mol.sup.-1 for C.sub.21 H.sub.25 N.sub.3 O.sub.3
Melting point: 141-143.degree. C.
Yield: 41%
Rf: 0.8 Eluent: methanol (saturated with ammonia)/chloroform (1:9)
Infrared spectrometry
2980-2740cm.sup.-1 .nu.CH
1670 cm.sup.-1 .nu.CO
1585 cm.sup.-1 .nu.C.dbd.C
______________________________________
Nuclear magnetic resonance spectrometry (300 MHz, DMSO-d.sub.6)
______________________________________
.delta.: 2.50 ppm
complex 4H piperazine
.delta.: 2.95 ppm
complex 4H piperazine
.delta.: 3.30 ppm
singlet 3H N--CH.sub.3
.delta.: 3.45 ppm
singlet 2H CH.sub.2
.delta.: 3.75 ppm
singlet 3H O--CH.sub.3
.delta.: 4.65 ppm
singlet 4H H.sub.2 (benzoxazine)
.delta.: 7.00 ppm
complex 7H H.sub.5, H.sub.6, H.sub.8 and
______________________________________
phenyl
EXAMPLE 8
4-METHYL-7-(4-(2-FLUOROPHENYL)-1-PIPERAZINYL)METHYL!-3-OXO-3,4-DIHYDRO-2H- 1,4-BENZOXAZINE
Stage A: 5-(4-(2-FLUOROPHENYL)-1 -PIPERAZINYL)METHYL!-2-(METHYLAMINO)PHENOL
Note: This compound forms part of the invention in the same way as the compound of Example 8.
The procedure is identical to that described for Example 7 Stage A, replacing 3-methyl-6-(4-(ortho-methoxyphenyl)-1-piperazinyl)methyl!benzoxazolinone hydrochloride by 3-methyl-6-(4-(ortho-fluorophenyl)-1 -piperazinyl)methyl!benzoxazolinone hydrochloride.
Reaction time: 2 hours
Molar mass: 315.39 g.mol.sup.-1 for C.sub.18 H.sub.22 FN.sub.3 O
Melting point: 170-171 .degree. C.
Yield: 79%
Recrystallization solvent: toluene
Rf: 0.5 Eluent: methanol (saturated with ammonia)/chloroform (1:9)
Infrared spectrometry
3420 cm.sup.-1 .nu.OH and .nu.NH
3040-2780 cm.sup.1 .nu.CH
1610 cm.sup.-1 .nu.C.dbd.C
______________________________________
Nuclear magnetic resonance spectrometry (300 MHz, DMSO-d.sub.6)
______________________________________
.delta.: 2.50 ppm
complex 4H piperazine
.delta.: 2.70 ppm
singlet 3H N--CH.sub.3
.delta.: 3.00 ppm
complex 4H piperazine
.delta.: 3.35 ppm
multiplet 2H CH.sub.2
.delta.: 4.70 ppm
signal 1H OH exchangeable with D.sub.2 O
.delta.: 6.35 ppm
doublet 1H H.sub.3 J.sub.3-4 = 8.15 Hz
.delta.: 6.50 ppm
doublet 1H H.sub.4 J.sub.4-3 = 8.15 Hz
.delta.: 6.60 ppm
singlet 1H H.sub.6
.delta.: 7.00 ppm
complex 4H phenyl
.delta.: 9.20 ppm
singlet 1H NH exchangeable with D.sub.2 O
______________________________________
Stage B: 4-METHYL-7-(4-(2-FLUOROPHENYL)-1 -PIPERAZINYL)METHYL!-3-OXO-3,4-DIHYDRO-2H-1,4-BENZOXAZINE
The procedure is identical to that described for obtaining Example 7 Stage B from Example 7 Stage A, using the compound obtained in Example 8 Stage A.
Reaction time: 16 hours
Molar mass: 355.41 g.mol.sup.-1 for C.sub.20 H.sub.22 FN.sub.3 O.sub.2
Melting point: 126-128.degree. C.
Yield: 36%
Recrystallization solvent: absolute ethanol
Rf: 0.8 Eluent: methanol (saturated with ammonia)/chloroform (1:9)
Infrared spectrometry
3000-2740 cm.sup.-1 .nu.CH
1670 cm.sup.1 .nu.CO
1605 cm.sup.-1 .nu.C.dbd.C
______________________________________
Nuclear magnetic resonance spectrometry (300 MHz, DMSO-d.sub.6)
______________________________________
.delta.: 2.50 ppm
complex 4H piperazine
.delta.: 3.00 ppm
complex 4H piperazine
.delta.: 3.30 ppm
singlet 3H N--CH.sub.3
.delta.: 3.50 ppm
singlet 2H CH.sub.2
.delta.: 4.65 ppm
singlet 2H H.sub.2 (benzoxazine)
.delta.: 7.00 ppm
complex 7H H.sub.5, H.sub.6, H.sub.8,
______________________________________
phenyl
EXAMPLE 9
4-METHYL-7-(4-(4-CHLOROPHENYL)-1-PIPERAZINYL)METHYL!-3-OXO-3,4-DIHYDRO-2H- 1,4-BENZOXAZINE
Stage A: 5-(4-(4-CHLOROPHENYL)-1-PIPERAZINYL)METHYL!-2-(METHYLAMINO)!PHENOL
This product forms part of the invention in the same way as Example 9, for which it constitutes a synthesis intermediate.
The procedure is identical to that described for obtaining Example 8 Stage A, using as starting material 3-methyl-6-(4-(4-para-chlorophenyl)-1 -piperazinyl)methyl)!benzoxazolinone.
Reaction time: 2 hours
Molar mass: 331.84 g.mol.sup.-1 for C.sub.18 H.sub.22 CIN.sub.3 O
Melting point: 159-160.degree. C.
Yield: 76%
Recrystallization solvent: toluene
Rf: 0.4 Eluent: methanol (saturated with ammonia)/chloroform (1:9)
Infrared spectrometry
3380 cm.sup.-1 .nu.OH and .nu.NH
2940-2780 cm.sup.-1 .nu.CH
1610 cm.sup.-1 .nu.C.dbd.C
1590 cm.sup.-1 .nu.C.dbd.C
______________________________________
Nuclear magnetic resonance spectrometry (300 MHz, DMSO-d.sub.6)
______________________________________
.delta.: 2.30 ppm
complex 4H piperazine
.delta.: 2.70 ppm
singlet 3H N--CH.sub.3
.delta.: 3.10 ppm
complex 4H piperazine
.delta.: 3.35 ppm
singlet 2H CH.sub.2
.delta.: 4.70 ppm
signal 1H OH exchangeable with D.sub.2 O
.delta.: 6.35 ppm
doublet 1H H.sub.3 J.sub.3-4 = 7.90 Hz
.delta.: 6.50 ppm
doublet 1H H.sub.4 J.sub.4-3 = 7.90 Hz
.delta.: 6.60 ppm
singlet 1H H.sub.6
.delta.: 6.90 ppm
doublet 2H H.sub.1', H.sub.5' (phenyl) J.sub.1'-2' =
J.sub.5'-4' = 8.65 Hz
.delta.: 7.20 ppm
doublet 2H H.sub.2', H.sub.4' (phenyl) J.sub.2'-1' =
J.sub.4'-5' = 8.65 Hz
.delta.: 9.20 ppm
singlet 1H NH exchangeable with D.sub.2 O
______________________________________
Stage B: 4-METHYL-7-(4-(4-CHLOROPHENYL)-1-PIPERAZINYL)METHYL!-3-OXO-3,4-DIHYDRO-2H -1,4-BENZOXAZINE HYDROCHLORIDE
The procedure is identical to that described for obtaining Example 7 Stage B, using as starting material the product obtained in Stage A of Example 9. The product is purified on a column of silica gel with the eluent: dichloromethane/methanol (9.9:0.1). The compound is solubilized in the minimum of acetone, and 100 cm.sup.3 of anhydrous ether saturated with gaseous hydrochloric acid are added. The precipitate is filtered off, washed with ether, dried and then recrystallized.
Molar mass: 408.32 g.mol.sup.-1 for C.sub.20 H.sub.23 Cl.sub.2 N.sub.3 O.sub.2
Melting point: 243-244.degree. C.
Yield: 32%
Recrystallization solvent: 95.degree. strength ethanol
Rf: 0.8 Eluent: methanol (saturated with ammonia)/chloroform (1:9)
Infrared spectrometry
2980-2820 cm.sup.-1 .nu.CH
2720-2300 cm.sup.-1 .nu.NH.sup.+
1685 cm.sup.-1 .nu.CO
1615 cm.sup.-1 .nu.C.dbd.C
1590 cm.sup.-1 .nu.C.dbd.C
______________________________________
Nuclear magnetic resonance spectrometry (300 MHz, DMSO-d.sub.6)
______________________________________
.delta.: complexpm 11H N--CH.sub.3, and piperazine
.delta.: singletpm 2H CH.sub.2
.delta.: singletpm 2H H.sub.2 (benzoxazine)
.delta.: complexpm 2H H.sub.5, H.sub.6
.delta.: complexpm 5H H.sub.8 and phenyl
.delta.: 11.60 ppm
signal 1H NH.sup.+ exchangeable with D.sub.2 O
______________________________________
EXAMPLE 10
6-(4-(2-FLUOROPHENYL)-1-PIPERAZINYL)METHYL!-BENZOXAZOLINONE
0.010 mol of 6-(chloromethyl)benzoxazolinone, 0.012 mol of N-(ortho)-fluorophenylpiperazine, 0.020 mol of triethylamine and 0.001 mol of potassium iodide are added to 50 cm.sup.3 of acetone. The mixture is heated to reflux for 2 days with magnetic stirring. The inorganic residue is filtered off and the acetone is evaporated off. 30 cm.sup.3 of 1N hydrochloric acid and 20 cm.sup.3 of ethyl acetate are added. The mixture is left for 30 minutes with magnetic stirring. The precipitate obtained is filtered off and washed several times with ethyl acetate. The product in hydrochloride form is obtained in base form in ethyl acetate in the presence of triethylamine. The product is dried and then recrystallized in toluene.
Molar mass: 327.36 g.mol.sup.-1 for C.sub.18 H.sub.18 FN.sub.3 O.sub.2
Melting point: 177-179.degree. C.
Yield: 46%
Rf: 0.4 Eluent: methanol (saturated with ammonia)/chloroform (1:9)
Infrared spectrometry
3240 cm.sup.-1 .nu.NH
2960-2740 cm.sup.-1 .nu.CH
1760 cm.sup.-1 .nu.CO--O
1610 cm.sup.-1 .nu.C.dbd.C
______________________________________
Nuclear magnetic resonance spectrometry (300 MHz, DMSO-d.sub.6)
______________________________________
.delta.: 2.50 ppm
complex 4H piperazine
.delta.: 3.00 ppm
complex 4H piperazine
.delta.: 3.50 ppm
singlet 2H CH.sub.2
.delta.: 7.00 ppm
complex 6H H.sub.4, H.sub.5 and phenyl
.delta.: 7.20 ppm
singlet 1H H.sub.7
.delta.: 11.50 ppm
singlet 1H NH exchangeable with D.sub.2 O
______________________________________
EXAMPLE 11
3-2-(4-(4-FLUOROBENZOYL)-1-PIPERIDYL)ETHYL!-6-(4-(2-FLUOROPHENYL)-1-PIPER AZINYL)METHYL!BENZOX-AZOLINONE
0.010 mol of 6-(4-(ortho-fluorophenyl)-1 -piperazinyl)methyl!benzoxazolinone and 0.060 mol of potassium carbonate are introduced into 50 cm.sup.3 of anhydrous dimethylformamide. The mixture is stirred for 30 minutes under reflux and 0.012 mol of 1-(2-chloroethyl)-4-(para-fluorobenzoyl)piperidine hydrochloride is added. The mixture is heated to reflux for 3 hours with magnetic stirring. It is cooled, the inorganic solid is filtered off and the filtrate is poured into 100 cm.sup.3 of ice-cold water. The precipitate formed is filtered off, washed with water, dried and then recrystallized in absolute ethanol.
Molar mass: 560.64 g.mol.sup.-1 for C.sub.32 H.sub.34 F.sub.2 N.sub.4 O.sub.3
Melting point: 124-126.degree. C.
Yield: 82%
Rf: 0.7 Eluent: methanol (saturated with ammonia)/chloroform (1:9)
Infrared spectrometry
2960-2740 cm.sup.-1 .nu.CH
1775 cm.sup.-1 .nu.CO--O
1670 cm.sup.-1 .nu.CO
1600 cm.sup.-1 .nu.C.dbd.C
______________________________________
Nuclear magnetic resonance spectrometry (300 MHz, DMSO-d.sub.6)
______________________________________
.delta.: 1.45 ppm
multiplet 2H piperidine
.delta.: 1.70 ppm
multiplet 2H piperidine
.delta.: 2.15 ppm
multiplet 2H piperidine
.delta.: 2.50 ppm
complex 4H piperazine
.delta.: 2.65 ppm
triplet 2H CH.sub.2 -piperidine J.sub.e-d = 5.95 Hz
.delta.: 3.00 ppm
complex 6H piperazine and piperdine
.delta.: 3.35 ppm
multiplet 1H piperidine-CO
.delta.: 3.55 ppm
singlet 2H CH.sub.2 -piperazine
.delta.: 3.90 ppm
triplet 2H CH.sub.2 --CH.sub.2 -piperidine J.sub.d-e = 5.95
Hz
.delta.: 7.05 ppm
complex 5H H.sub.4 and phenyl(piperazine)
.delta.: 7.30 ppm
complex 4H H.sub.5, H.sub.7 and benzoyl(piperidine)
.delta.: 8.00 ppm
complex 2H benzoyl(piperidine)
______________________________________
EXAMPLE 12
6-(4-(2-FLUOROPHENYL)-1-PIPERAZINYL)METHYL!-BENZOTHIAZOLINONE HYDROCHLORIDE
0.010 mol of 6-(chloromethyl)benzothiazolinone, 0.012 mol of N-(ortho-fluorophenyl)-piperazine, 0.020 mol of triethylamine and 0.001 mol of potassium iodide are added to 50 cm.sup.3 of acetone. The mixture is heated to reflux for 2 days with magnetic stirring. The inorganic residue is filtered off and the acetone is evaporated off. 30 cm.sup.3 of 1N hydrochloric acid and 20 cm.sup.3 of ethyl acetate are added. The mixture is left for 30 minutes with magnetic stirring. The precipitate obtained is filtered off and washed several times with ethyl acetate. The product is dried and then recrystallized in 95.degree. strength ethanol.
Molar mass: 379.88 g.mol.sup.-1 for C.sub.18 H.sub.19 CIFN.sub.3 OS
Melting point: >260.degree. C.
Yield: 61%
Rf: 0.5 Eluent: methanol (saturated with ammonia)/chloroform (1:9)
Infrared spectrometry
15 3120 cm.sup.-1 .nu.NH
2940-2820 cm.sup.-1 .nu.CH
2740-2540 cm.sup.-1 .nu.NH.sup.+
1670 cm.sup.1 .nu.CO--S
1610 cm.sup.-1 .nu.C.dbd.C
______________________________________
Nuclear magnetic resonance spectrometry (300 MHz, DMSO-d.sub.6)
______________________________________
.delta.: 3.10 ppm
complex 4H piperazine
.delta.: 3.50 ppm
complex 4H piperazine
.delta.: 4.50 ppm
singlet 2H CH.sub.2
.delta.: 7.10 ppm
complex 5H H.sub.4 phenyl
.delta.: 7.50 ppm
doublet 1H H.sub.5 J.sub.5-4 = 8.20 Hz
.delta.: 7.80 ppm
singlet 1H H.sub.7
.delta.: 9.70 ppm
signal 1H NH.sup.+ exchangeable with D.sub.2 O
.delta.: 12.15 ppm
singlet 1H NH exchangeable with D.sub.2 O
______________________________________
EXAMPLE 13
3-2-(4-(4-FLUOROBENZOYL)-1-PIPERIDYL)ETHYL!-6-(4-(2-FLUOROPHENYL)-1-PIPER AZINYL)METHYL!-BENZOTHIAZOLINONE DIHYDROCHLORIDE
0.010 mol of 6-(4-(ortho-fluorophenyl)-1 -piperazinyl)methyl!benzothiazolinone and 0.060 mol of potassium carbonate are introduced into 50 cm.sup.3 of anhydrous dimethyl formamide. The mixture is stirred for 30 minutes under reflux and 0.012 mol of 1-(2-chloroethyl)-4-(para-fluorobenzoyl)piperidine hydrochloride is added. The mixture is heated to reflux for 1 hour with magnetic stirring. It is cooled, the inorganic solid is filtered off and the filtrate is poured into 100 cm.sup.3 Of ice-cold water. The precipitate formed is filtered off, washed with water and then dried. The product is solubilized in the minimum of acetone, and 100 cm.sup.3 of anhydrous ether saturated with gaseous hydrochloric acid are added. The precipitate is filtered off, washed with ether, dried and then recrystallized in absolute ethanol.
Molar mass: 649.63 g.mol.sup.-1 for C.sub.32 H.sub.36 Cl.sub.2 F.sub.2 N.sub.4 O.sub.2 S
Melting point: 251-253.degree. C.
Yield: 56%
Rf: 0.6 Eluent: methanol (saturated with ammonia)/chloroform (1:9)
Infrared spectrometry
3060-2800 cm.sup.-1 .nu.CH
2740-2280 cm.sup.-1 .nu.NH.sup.+
1670 cm.sup.-1 .nu.CO--S and .nu.CO
1590 cm.sup.-1 .nu.C.dbd.C
______________________________________
Nuclear magnetic resonance spectrometry (300 MHz, DMSO-d.sub.6)
______________________________________
.delta.: 2.00 ppm
complex 4H piperidine
.delta.: 3.20 ppm
complex 4H piperazine
.delta.: 3.45 ppm
complex 11H piperazine, piperidine, CH.sub.2 -piperidine
.delta.: 4.45 ppm
complex 4H CH.sub.2 -piperazine, CH.sub.2 --CH.sub.2
piperidine
.delta.: 7.10 ppm
complex 4H phenyl(piperazine)
.delta.: 7.40 ppm
complex 2H H.sub.4, H.sub.5
.delta.: 4.45 ppm
complex 4H CH.sub.2 -piperazine
.delta.: 7.80 ppm
complex 2H benzoyl(piperidine)
.delta.: 8.00 ppm
singlet 1H H.sub.7
.delta.: 8.10 ppm
complex 2H benzoyl(piperidine)
.delta.: 11.25 ppm
signal 1H NH.sup.+ exchangeable with D.sub.2 O
.delta.: 11.70 ppm
signal 1H NH.sup.+ exchangeable with D.sub.2 O
______________________________________
EXAMPLE 14
3-METHYL-6-(4-(BENZOd!-1,2-THIAZOLYL)-1-PIPERAZINYL)METHYL!BENZOTHIAZOLIN ONE
0.010 mol of 3-methyl-6-(chloromethyl)benzothiazolinone, 0.012 mol of 1-(3-benzisothiazolyl)piperazine, 0.020 mol of triethylamine and 0.001 mol of potassium iodide are added to 50 cm.sup.3 of acetone. The mixture is heated to reflux with magnetic stirring for 2 days. The inorganic residue is filtered off and the acetone is evaporated off. 30 cm.sup.3 of 1N hydrochloric acid and 20 cm.sup.3 of ethyl acetate are added. The mixture is left for 30 minutes with magnetic stirring. The precipitate obtained is filtered off and washed several times with ethyl acetate. The product in hydrochloride form is converted to base form in ethyl acetate in the presence of triethylamine. The product is dried and then recrystallized in methanol.
Molar mass: 396.53 g.mol.sup.-1 for C.sub.20 H.sub.20 N.sub.4 OS.sub.2
Melting point: 163-165.degree. C.
Yield: 31%
Rf: 0.8 Eluent: methanol (saturated with ammonia)/chloroform (1:9)
Infrared spectrometry
2980-2760 cm.sup.-1 .nu.CH
1665 cm.sup.-1 .nu.CO--S
1580 cm.sup.-1 .nu.C.dbd.C
______________________________________
Nuclear magnetic resonance spectrometry (300 MHz, DMSO-d.sub.6)
______________________________________
.delta.: 2.60 ppm
complex 4H piperazine
.delta.: 3.40 ppm
complex 7H N--CH.sub.3, and piperazine
.delta.: 3.60 ppm
singlet 2H CH.sub.2
.delta.: 7.30 ppm
doublet 1H H.sub.4 J.sub.4-5 = 8.00 Hz
.delta.: 7.40 ppm
doublet 1H H.sub.5 J.sub.5-4 = 8.00 Hz
.delta.: 7.50 ppm
complex 2H benzisothiazole
.delta.: 7.65 ppm
singlet 1H H.sub.7
.delta.: 8.05 ppm
complex 2H benzisothiazole
______________________________________
EXAMPLE 15
3-METHYL-6-(4-(BENZOd!-1,2-THIAZOLYL)-1-PIPERAZINYL)-METHYL!BENZOXAZOLINO NE
0.010 mol of 3-methyl-6-(chloromethyl)benzoxazolinone, 0.012 mol of 1-(3-benzisothiazolyl)piperazine, 0.020 mol of triethylamine and 0.001 mol of potassium iodide are added to 50 cm.sup.3 of acetone. The mixture is heated to reflux with magnetic stirring for 3 days. The inorganic residue is filtered off and the acetone is evaporated off. 30 cm.sup.3 of 1N hydrochloric acid and 20 cm.sup.3 of ethyl acetate are added. The mixture is left for 30 minutes with magnetic stirring. The precipitate obtained is filtered off and washed several times with ethyl acetate. The product in hydrochloride form is converted to base form in ethyl acetate in the presence of triethylamine. The product is dried and then recrystallized in absolute ethanol.
Molar mass: 380.47 g.mol.sup.-1 for C.sub.20 H.sub.20 N.sub.4 O.sub.2 S
Melting point: 193-194.degree. C.
Yield: 72%
Rf: 0.6 Eluent: methanol (saturated with ammonia)/chloroform (1:9)
Infrared spectrometry
3080-2760 cm.sup.-1 .nu.CH
1760 cm.sup.-1 .nu.C--O
1620 cm.sup.-1 .nu.C.dbd.C
1590 cm.sup.-1 .nu.C.dbd.C
______________________________________
Nuclear magnetic resonance spectrometry (300 MHz, DMSO-d.sub.6)
______________________________________
.delta.: 2.60 ppm
complex 4H piperazine
.delta.: 3.35 ppm
singlet 3H N--CH.sub.3
.delta.: 3.50 ppm
complex 4H piperazine
.delta.: 3.60 ppm
singlet 2H CH.sub.2
.delta.: 7.20 ppm
complex 2H H.sub.4, H.sub.5
.delta.: 7.30 ppm
singlet 1H H.sub.7
.delta.: 7.50 ppm
complex 2H benzisothiazole
.delta.: 8.05 ppm
complex 2H benzisothiazole
______________________________________
EXAMPLE 16
4-METHYL-7-(4-(BENZOd!-1,2-THIAZOLYL)-1-PIPERAZINYL)METHYL!-3-OXO-3,4-DIH YDRO-2H-1,4-BENZO-XAZINE HYDROCHLORIDE
Stage A: 5-(4-(3-BENZISOTHIAZOLYL)-1-PIPERAZINYL)METHYL!-2-(METHYL-AMINO)PHENOL
This product forms part of the invention in the same way as Example 16, for which it constitutes a synthesis intermediate.
0.08 mol of sodium hydroxide is dissolved in 5 cm.sup.3 of water, and 25 cm.sup.3 of methanol and 0.01 mol of 3-methyl-6-(4-(3-benzisothiazolyl)-1-piperazinyl)methyl!benzoxazolinone hydrochloride are then added. The mixture is heated to reflux with magnetic stirring for 2 hours. The methanol is evaporated off under reduced pressure and the residue is then dissolved in 50 cm.sup.3 of water. The solution is placed in a bath of ice-cold water, 6N hydrochloric acid is added until the pH=1, and the mixture is then alkalinized with 10% aqueous potassium carbonate solution until the pH=8-9. The mixture is stirred for 30 minutes. The precipitate obtained is filtered off, washed with water until the washing liquors are neutral, dried and then recrystallized in toluene.
Molar mass: 354.47 g.mol.sup.-1 for C.sub.19 H.sub.22 N.sub.4 OS
Melting point: 153-154.degree. C.
Yield: 55%
Recrystallization solvent: toluene
Rf: 0.4 Eluent: methanol (saturated with ammonia)/chloroform (1:9)
Infrared spectrometry
3320 cm.sup.-1 .nu.OH and .nu.NH
3060-2760 cm.sup.-1 .nu.CH
1610 cm.sup.-1 .nu.C.dbd.C
1590 cm.sup.-1 .nu.C.dbd.C
______________________________________
Nuclear magnetic resonance spectrometry (300 MHz, DMSO-d.sub.6)
______________________________________
.delta.: 2.55 ppm
complex 4H piperazine
.delta.: 2.70 ppm
singlet 3H N--CH.sub.3
.delta.: 3.40 ppm
complex 6H CH.sub.2,
piperazine
.delta.: 4.70 ppm
signal 1H OH exchangeable with D.sub.2 O
.delta.: 6.40 ppm
doublet 1H H.sub.3
J.sub.3-4 = 7.50 Hz
.delta.: 6.60 ppm
doublet 1H H.sub.4
J.sub.4-3 = 7.50 Hz
.delta.: 6.70 ppm
singlet 1H H.sub.7
.delta.: 7.50 ppm
complex 2H benziso-
thiazole
.delta.: 8.00 ppm
complex 2H benziso-
thiazole
.delta.: 9.20 ppm
singlet 1H NH exchangeable with D.sub.2 O
______________________________________
Stage B: 4-METHYL-7-(4-(3-BENZOd!1,2-THIAZOLYL)-1-PIPERAZINYL)METHYL!-3-OXO-3,4-D IHYDRO-2H-1,4-BENZOXAZINE HYDROCHLORIDE
0.01 mol of sodium is dissolved in 40 cm.sup.3 of absolute ethanol. The absolute ethanol is evaporated off, and 20 cm.sup.3 of dimethyl sulfoxide and 0.01 mol of 5-(4-(3-benzisothiazolyl)-1-piperazinyl)methyl!-2-(methylamino)phenol are then added. The mixture is stirred for 30 minutes, 0.01 mol of ethyl bromoacetate is added, and the mixture is then left at room temperature with magnetic stirring for 16 hours. It is hydrolyzed in 100 cm.sup.3 of ice-cold water, and the solution is acidified with 1N hydrochloric acid until the pH=1 and then alkalinized with 10% aqueous potassium carbonate solution until the pH=8-9. The mixture is stirred for 1 hour. The precipitate is filtered off, washed with water until the washing liquors are neutral, dried and then purified on a column of silica gel with the eluent, dichloromethane/methanol (9.8: 0.2). The product is solubilized in the minimum of acetone, and 100 cm.sup.3 of ether saturated with gaseous hydrochloric acid are added. The mixture is stirred for 30 minutes. The precipitate is filtered off, washed with ether, dried and then recrystallized in absolute ethanol.
Molar mass: 430.96 g.mol.sup.-1 for C.sub.21 H.sub.23 CIN.sub.4 O.sub.2 S
Melting point: 248-250.degree. C.
Yield: 63%
Rf: 0.6 Eluent: methanol (saturated with ammonia)/chloroform (1:9)
Infrared spectrometry
3060-2820 cm.sup.-1 .nu.CH
2720-2420 cm.sup.-1 .nu.NH.sup.+
1680 cm.sup.-1 .nu.CO
1610 cm.sup.-1 .nu.C.dbd.C
1590 cm.sup.-1 .nu.C.dbd.C
______________________________________
Nuclear magnetic resonance spectrometry (300 MHz, DMSO-d.sub.6)
______________________________________
.delta.: 3.30 ppm
singlet 3H N--CH.sub.3
.delta.: 3.50 ppm
complex 8H piperazine
.delta.: 4.40 ppm
singlet 2H CH.sub.2
.delta.: 4.70 ppm
singlet 2H H.sub.2
(benzoxazine)
.delta.: 7.25 ppm
doublet 1H H.sub.5
J.sub.5-6 = 8.40 Hz
.delta.: 7.35 ppm
complex 2H H.sub.6, H.sub.8
.delta.: 7.60 ppm
complex 2H benziso-
thiazole
.delta.: 8.10 ppm
complex 2H benziso-
thiazole
.delta.: 11.30 ppm
signal 1H NH.sup.+
exchangeable with D.sub.2 O
______________________________________
EXAMPLE 17
3-{2-4-(4',4"-DIFLUOROBENZHYDRYLIDENE)-1-PIPERIDINYL!ETHYL}-6-(4-(2-FLUOR OPHENYL)-1-PIPERAZINYL)METHYL!BENZOXAZOLINONE DIHYDROCHLORIDE
Using the procedure described in Example 11, but replacing 1-(2-chloroethyl)-4-(para-fluorobenzoyl)piperidine by 1-(2-chloroethyl)-4-(4',4"-difluorobenzhydrylidene)-piperidine, the product of the title is obtained.
Using the same procedure as in Examples 1 to 17, but using the appropriate starting materials, the compounds of Examples 18 to 26 are obtained:
EXAMPLE 18
3-METHYL-6-{4-(4-AMINOSULFONYLPHENYL)-1-PIPERAZINYL!-METHYL}BENZOXAZOLINON E HYDROCHLORIDE
EXAMPLE 19
3-METHYL-6-{4-(4-AMINOSULFONYLPHENYL)-1-PIPERAZINYL!-METHYL}BENZOTHIAZOLIN ONE HYDROCHLORIDE
EXAMPLE 20
4-METHYL-7-{4-(4-AMINOSULFONYLPHENYL)-1-PIPERAZINYL!METHYL}-3-OXO-3,4-DIHY DRO-2H-1,4-BENZOXAZINE HYDROCHLORIDE
EXAMPLE 21
3-METHYL-6-{4-(3-METHOXYPHENYL)-1-PIPERAZINYL!METHYL}-BENZOTHIAZOLINONE HYDROCHLORIDE
Melting point: 208-210.degree. C.
EXAMPLE 22
3-METHYL-6-{4-(3-METHOXYPHENYL)-1-PIPERAZINYL!METHYL}-BENZOXAZOLINONE HYDROCHLORIDE
Melting point: 227-229.degree. C.
EXAMPLE 23
4-METHYL-7-{4-(3-METHOXYPHENYL)-1-PIPERAZINYL!METHYL}-3-OXO-3,4-DIHYDRO-2H -1,4-BENZOXAZINE HYDROCHLORIDE
Melting point: 188-190.degree. C.
EXAMPLE 24
4-METHYL-7-{4-(4-METHOXYPHENYL)-1-PIPERAZINYL!METHYL}-3-OXO-3,4-DIHYDRO-2H -1,4-BENZOXAZINE HYDROCHLORIDE
Melting point: 156-158.degree. C.
EXAMPLE 25
3-METHYL-6-{4-(4-METHOXYPHENYL)-1-PIPERAZINYL!METHYL}-BENZOTHIAZOLINONE HYDROCHLORIDE
Melting point: >260.degree. C.
EXAMPLE 26
3-METHYL-6-{4-(4-METHOXYPHENYL)-1-PIPERAZINYL!METHYL}-BENZOXAZOLINONE HYDROCHLORIDE
Melting point: >250.degree. C.
Pharmacological Study of the Compounds of the Invention
EXAMPLE A
IN VITRO AFFINITY TEST FOR THE D.sub.4, D.sub.2, and 5-HT.sub.1A RECEPTORS
The in vitro affinity tests for the 5-HT.sub.1A, D4 and D.sub.2 receptors were carried out according to classical binding techniques.
The results of these studies show that the compounds of the invention possess a K.sub.i of the order of 10.sup.-7 M with respect to the 5-HT.sub.1A and D.sub.2, receptors, equivalent to an approximately 1 00-fold lower affinity than the compounds of Application EP 478446.
The affinity for the D.sub.4.4 receptors was determined by competitive experiments with .sup.3 H!spiperone (NEN, les Ulis, France). Membranes prepared from CHO cells transfected with the human D.sub.4.4 receptor were purchased from Receptor Biology Inc. (Md., USA). The membranes (30 .mu.g of membrane protein) are incubated in triplicate with 0.5 nM .sup.3 H!spiperone and the cold ligand in a final volume of 0.5 ml for 60 min at 25.degree. C. The incubation buffer contains 50 nM TRIS-HCI (pH 7.4), 120 mM NaCl, 5 mM KCl, 5 mM MgCl.sub.2 and 1 mM EDTA. Nonspecific binding is determined with 10 .mu.M haloperidol. At the end of the incubation, the incubation medium is filtered through WHATMAN GF/B filters impregnated with 0.1% of polyethyleneimine and washed three times with 2 ml of cooled buffer. The radioactivity retained on the filters is determined by liquid scintillation counting. The binding isotherms are analyzed by nonlinear regression using "PRISM" software (GraphPad Software Inc., S. Diego, USA) to determine IC.sub.50 values. The latter are converted to the dissociation constant (K.sub.i) by means of the Cheng-Prusoff equation:
K.sub.i =IC.sub.50 /{(L/K.sub.d)-1}
in which L is the concentration of .sup.3 H!spiperone and K.sub.d is the 3H!spiperone dissociation constant of the human D.sub.4.4 receptor (70 pM).
For the D.sub.4.4 receptors, the affinity K.sub.i is of the order of 10.sup.-8 -10.sup.-9, whereas the compounds of Application EP 478446 only had an affinity of the order of 10.sup.-6 M.
EXAMPLE B
DETERMINATION OF THE EFFICACY AT THE HUMAN D.sub.4.4 RECEPTORS
The efficacy was determined by measuring the activation of G proteins by stimulating the binding of .sup.35 S!GTP.gamma.S (NEN, Les Ulis, France). The membranes prepared from CHO cells transfected with the human D.sub.4.4 receptor were purchased from Receptor Biology Inc. (Md., USA). The membranes (50 .mu.g of membrane protein) are incubated in triplicate with 0.1 nM .sup.35 S!GTP.gamma.S and the cold ligand in a final volume of 0.5 ml for 20 min at 25.degree. C. The incubation buffer contains 20 mM HEPES (pH 7.4), 3 .mu.M GDP, 3 mM MgCl.sub.2 and 100 mM NaCl. At the end of the incubation, the incubation medium is filtered through WHATMAN GF/B filters impregnated with water and washed three times with 2 ml of cooled buffer. The radioactivity retained on the filters is determined by liquid scintillation counting. The binding isotherms are analyzed by nonlinear regression using `PRISM` software (GraphPad Software Inc., S. Diego, USA) to determine EC.sub.50 and efficacy (E.sub.max) values. The efficacy is expressed as a percentage of the stimulation of the binding of .sup.35 S!GTP.gamma.S induced by dopamine.
For the tests of antagonism, the membranes are preincubated with the antagonist at a fixed concentration of dopamine for 30 min before adding the .sup.35 S!GTP.gamma.S. The IC.sub.50 values are converted to the antagonist potency constant (K.sub.b) by means of the following equation:
K.sub.b =IC.sub.50 /{Antagonist!/EC.sub.50 !+1 }
in which Antagonist! is the antagonist concentration and EC.sub.50 is the EC.sub.50 determined in the absence of antagonist (dopamine alone).
For Example 1, the K.sub.b is 2.39.+-.1.10 nM.
For Example 3, the K.sub.b is 16.1.+-.5.0 nM.
EXAMPLE C
ACUTE TOXICITY
The acute toxicity was assessed after oral administration to groups of 8 mice (26.+-.2 grams) of a dose of 650 mg.kg.sup.-1. The animals were observed at regular intervals during the first day and daily for the two weeks following the treatment.
It is apparent that most of the compounds of the invention are completely nontoxic. Most of them do not give rise to any death after administration at a dose of 650 mg.kg.sup.-1, and no disorders are generally noted after administration of this dose.
PHARMACEUTICAL COMPOSITIONS
Tablets intended for the treatment of mental disorders, containing a 1 mg dose of 3-methyl -6-(4-(2-fluorophenyl)-1-piperazinyl)methyl!benzothiazolinone hydrochloride.
Preparation formula for 1000 tablets:
3-Methyl-6-(4-(2-fluorophenyl)-1-piperazinyl)methyl!benzoxathiazolinone
hydrochloride 1 g
Wheat starch 20 g
Corn starch 20 g
Lactose 65 g
Magnesium stearate 2 g
Silica 1 g
Hydroxypropylcellulose 2 g
|
|
